Provider review
Bliv review
Low entry figures, all of them floors, with a financing installment among them.
Financing is offered openly and there are no hidden subscriptions. Every number on the page is a floor, and the smallest one is not a treatment price.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
Bliv
From $116/mo sema · $199/mo dual-action, all quoted as floors
- Vs median
- $53/mo below the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
The entry figures here are competitive and the financing is handled honestly — pay-later eligibility is stated up front rather than surfacing at checkout, and the site says plainly that there are no hidden subscriptions, which is a specific and checkable promise where most sellers offer a vague one. What makes the page harder to use than it should be is that every number on it is a floor. The semaglutide figure, the dual-action figure and the financing figure are all introduced the same way, so a reader leaves with three lower bounds and no sense of what any of them rises to. The smallest of the three deserves particular care: it describes a payment-plan installment rather than the cost of treatment, and it sits close enough to the medication prices in both placement and formatting to be read as one of them. Nothing published attaches a dose to any figure, and the dual-action product is described by its mechanism without the molecule being named, so a reader is left inferring what they would actually be taking.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want financing stated openly before checkout rather than discovered at it.
- You want a specific promise about no hidden subscriptions.
- You are scanning the low end of the market for an entry figure.
Look elsewhere if
- You need a ceiling. Every figure on the page is a floor.
- You see the smallest number as a treatment price. It is a financing installment.
- You want to know which molecule the dual-action option contains. It is not named.
What it actually costs
Price as published
Compounded semaglutide "as low as $116" a month and a dual-action option "as low as $199", with a third figure of "as low as $29" attached to flexible payment rather than to a medication · ★ "no hidden subscriptions" is stated alongside the pricing and financing is offered openly — "pay later eligible, with options starting around $116/month" · every figure on the page is an "as low as", including the financing one, so a reader learns three floors and no ceilings · the $29 in particular describes a payment plan installment rather than the cost of treatment, and sits close enough to the medication figures to be mistaken for one · no dose is published behind any figure and no molecule is attached to the dual-action option by name
- Vs median
- $53/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. Semaglutide carries a floor figure readable before intake. The dual-action option is described by mechanism with no molecule named, and a third figure on the page is a FINANCING installment rather than a treatment cost. Every figure is an "as low as". No low-dose product is offered.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Entry figures for both options sit at the low end of the published field.
- Financing is offered openly and stated before checkout rather than after.
- States plainly that there are no hidden subscriptions.
Pharmacy, labs and oversight
Bliv dispenses through a Not named facility. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
3 of 4 published openly
What Bliv publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
The entry figures here are competitive and the financing is presented honestly — pay-later eligibility is stated up front rather than surfacing at checkout, and the site says plainly that there are no hidden subscriptions, which is a specific and checkable promise rather than a vague one. What makes the page harder to use is that every number on it is a floor. The semaglutide figure, the dual-action figure and the financing figure are all introduced as "as low as", so a reader comes away with three lower bounds and no idea what any of them rises to. The smallest of the three is the one to watch: it describes a payment-plan installment rather than the cost of treatment, and it sits close enough to the medication prices in both placement and format to be read as one. Nothing published attaches a dose to any figure, and the dual-action product is described by mechanism without the molecule being named, so a reader has to infer what they would actually be taking.
The honest cons
Every published figure is an "as low as" with no ceiling stated anywhere.
- The smallest figure is a financing installment, not the cost of treatment.
- No dose is published, and the dual-action product is not named by molecule.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Bliv is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#213 of 373
Ordered with the companies that pay us first, and Bliv is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Microdosing tirzepatide
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.